Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Neutral on Pinterest, Lowers Price Target to $42

Citigroup analyst Jason Bazinet maintains Pinterest (NYSE:PINS) with a Neutral and lowers the price target from $48 to $42.

byBenzinga Newsdesk

December 22, 2021

1 minute read

Citigroup analyst Jason Bazinet maintains Pinterest (NYSE:PINS) with a Neutral and lowers the price target from $48 to $42.

Raymond James Maintains Outperform on Xenia Hotels & Resorts, Raises Price Target to $21

By Benzinga Newsdesk

Today, 11:13 PM

Raymond James maintains Xenia Hotels & Resorts (NYSE:XHR) with a Outperform and raises the price target from $20 to $21.

XHR

Raymond James Maintains Outperform on Mastercard, Lowers Price Target to $447

By Benzinga Newsdesk

Today, 11:13 PM

Raymond James analyst John Davis maintains Mastercard (NYSE:MA) with a Outperform and lowers the price target from $453 to $447.

Keybanc Maintains Overweight on Duke Energy, Raises Price Target to $119

By Benzinga Newsdesk

Today, 11:13 PM

Keybanc analyst Sophie Karp maintains Duke Energy (NYSE:DUK) with a Overweight and raises the price target from $110 to $119.

DUK

SciSparc Announces Additional Results From The Third Part Of Clearmind Medicine Inc. Pre-Clinical Study For Cocaine Addiction Treatment

By Benzinga Newsdesk

Today, 11:13 PM

The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. TEL AVIV, Israel,

SPRC

Citigroup Maintains Neutral on Pinterest, Lowers Price Target to $42

Related Posts

Raymond James Maintains Outperform on Xenia Hotels & Resorts, Raises Price Target to $21

Raymond James Maintains Outperform on Mastercard, Lowers Price Target to $447

Keybanc Maintains Overweight on Duke Energy, Raises Price Target to $119

SciSparc Announces Additional Results From The Third Part Of Clearmind Medicine Inc. Pre-Clinical Study For Cocaine Addiction Treatment